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Abstract
Bloodstream infection (BSI) and associated sepsis represent a major source of mortality in
industrialized countries. Prompt treatment with targeted antibiotics affects both the financial
impact and the clinical outcome of BSI: every hour gained in initiating the correct antimicrobial
therapy significantly increases the probability of patient survival. However, the current stan-
dard-of-care, which depends on blood culture-based diagnosis, are often unable to provide
such a fast response. Fast and sensitive molecular techniques for the detection of sepsis-
related pathogens from primary blood samples are strongly needed. The aim of this study
was to assess the usefulness of the IRIDICA BAC BSI Assay, a PCR/ESI-MS-based technol-
ogy for the early diagnosis of bloodstream infections from primary blood samples in critical
patients. This evaluation has been performed by comparison with the traditional culture-
based methods. The study was performed on a total of 300 prospective whole blood speci-
mens obtained from patients suspected of sepsis, admitted to enrolling ER units from The
Greater Romagna Area. The overall concordance between the two techniques was of 86%,
with a calculated sensitivity of 76% and an assay specificity of 90%. The clinical significance
of discrepant results was evaluated reviewing the patients’ clinical records and the results of
additional relevant microbiological tests. The data here obtained support the ability of the IRI-
DICA BAC BSI Assay to identify a broad range of bacteria directly from primary whole blood
samples, within eight hours. This might allow a timely administration of a suitable treatment.
Introduction
Bloodstream infection (BSI) and associated sepsis represent a major issue in industrialized
countries [1], with an incidence of three cases per 1,000 individuals in Europe. Sepsis has been
shown as the third most frequent cause of death in Germany, and the incidence in France
increased by 75% in a ten-year span [2–4].
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Prompt treatment with targeted antibiotics affects both the financial impact and the clinical
outcome of BSI: every hour gained in initiating the correct antimicrobial therapy significantly
increases the probability of patient survival [1, 5–7]. However, the current standard-of-care,
which depends on blood culture-based diagnosis, are often unable to provide such a fast
response [8–10].
Although many infections can be detected after 24 to 48 hours, it may take up to 5-days
incubations to capture the majority of slow-growing bacteria and fungi associated with BSI,
and the antibiotic susceptibility determination require an additional 6 to 24 h [10–13].
A targeted therapy, therefore, only follows after several days of empirical treatment with broad-
spectrum antibiotics [14]. The empirical use of antibiotics results in a 15–30% rate of inappropriate
treatment, which is associated with a 2 to 5- fold increase in the mortality risk of septic patients
and a contributing factors in the recent increases in antibiotic-resistant organisms [14–15].
In addition to temporal issues, the diagnostic yeld needs to be considered. Conventional
microbiologic methods have a low diagnostic yield, especially in patients treated prior to sam-
pling [6,16], and are not sensitive to unculturable or fastidious organisms, which may be iden-
tified with molecular methods [3, 17–18]. However, such methods lack either the sensitivity to
identify sepsis-related pathogens directly from the primary sample or a wide enough panel of
identification [19–20].
Many culture-negative, molecular-positive detections are likely to be due to culture insensi-
tivity rather than a lack of specificity or clinical relevance of molecular methods [6, 19–21]:
many studies reported that these results are frequently confirmed in later cultures; addition-
ally, blood culture is positive in only 50% of cases where BSI is strongly suspected from a clini-
cal point of view [22–24].
Fast and sensitive molecular techniques for the detection of sepsis-related pathogens are
urgently needed, especially from primary blood samples [20].
The technology here presented is a universal PCR amplification coupled with mass spec-
trometry (PCR/ESI-MS) [21]. This method is based on a mismatch and background tolerant
PCR reaction, generating amplicons from BSI-related bacteria and Candida species [24–25].
The amplicons are analyzed through mass spectrometrometry; sequence variants are descrimi-
nated from a panel of more than 780 species [24, 26–27].
In this study we compared the performance of the IRIDICA BAC BSI Assay, performed on
the batch platform IRIDICA System (CE-IVD marked), to that of traditional culture-based
methods in a series of clinical whole blood specimens prospectively collected from patients
attending selected Units of the Emergency Department and Infectious Diseases of the Great
Romagna Health Authority. The aim was to evaluate the usefulness of this method for the
early diagnosis of bloodstream infections in patients with suspected sepsis.
Materials and methods
Ethics statement
Informed consent was obtained from all patients included in the study. This study was
approved by the Clinical Research Ethics Committee of IRST IRCCS-AVR (approval n. 1321/
11.06.2015).
Patients and specimens
300 whole blood samples were prospectively collected between May 1st 2016 and December
31st 2016 from consenting patients who presented to one of the units participating in the
study: Emergency Room and Emergency Medicine Units—Bufalini Hospital (Cesena, Italy),
Santa Maria delle Croci Hospital (Ravenna, Italy), Infermi Hospital (Rimini, Italy); Infectious
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Diseases Unit—Morgagni-Pierantoni Hospital (Forlı`, Italy), Emergency Medicine Unit—
Umberto I Hospital (Lugo, Italy). This study focused on a non-hospitalized population, as
these subjects were presumably not under previous antibiotic treatment, which might have
affected blood culture results [6,16]; blood withdrawals were performed approximately within
2 hours from admission. The chief selection criterion was a clinical suspicion of sepsis, in
accordance with the Third International Consensus Definition for Sepsis and Septic Shock:
sepsis is a life-threatening organ disfunction caused by a dysregulated response to infection.
Such disfunction is defined by an increase in the Sequential Sepsis-related Organ Failure
Assessment (SOFA) score of 2 points or more [28]. Patients were considered eligible for the
study if 18 years old or older, were able to personally provide the informed consent, and were
having blood cultures drawn as a part of standard clinical care. Specimens were collected in 10
ml EDTA blood tubes following blood draws taken for routine microbiology testing, using the
same venipunctures. Then, samples were refrigerated and transported from each hospital to
the Unit of Microbiology at the Greater Romagna Area Hub Laboratory in Pievesestina (FC),
with an average time of transport of 40 min. The cold chain was maintained and controlled
during the transport. Both the PCR/ESI-MS and the microbiology testing, including incuba-
tion, were performed at our Laboratory. The IRIDICA BAC BSI Assay and standard-of-care
testing were performed blindly to one another’s results. The reports from the microbiology
testing were used in this study as the comparative method to evaluate the IRIDICA System.
Specimen processing with conventional microbiological methods
The blood culture collection policy recommends a minimum of two sets of blood cultures
drawn for each patient suspected of sepsis. Processing multiple cultures is useful to increase
sensitivity and to discriminate true pathogens from contaminants [3, 29]. Each set consists of
an aerobic bottle (BacT/ALERT1 FA Plus, bioMe´rieux, Marcy l’Etoile, France) and an anaero-
bic lytic bottle (BacT/ALERT1 FN Plus, bioMe´rieux), containing adsorbent polymeric beads
for the neutralization of antimicrobial agents, which are inoculated with 10 mL of blood each.
When samples arrived at the Laboratory, the two sets of blood cultures were incubated in a
BacT/ALERT (bioMe´rieux) automated instrument for up to 5 days [13]; positive samples were
identified through time-of-flight mass spectrometry coupled with matrix-assisted laser desorp-
tion/ionization (MALDI-TOF) performed on Vitek MS (bioMe´rieux) instrument. The suscep-
tibility testing was achieved using the automated Vitek 2 (bioMe´rieux) system from positive
blood culture bottles after performing a Gram stain and a concentration procedure [11–13].
Specimen processing with IRIDICA–BAC BSI ASSAY
Prior to testing the clinical samples, the instrument functionality was tested through analysis
of five reference strains: methicillin-resistant Staphylococcus aureus, carbapenem-resistant
Klebsiella pneumoniae, vancomycin-resistant Enterocuccous faecium, vancomycin-resistant
Enterocuccous faecalis, Candida albicans (NATtrol™ ZeptoMetrix Corporation, U.S.A.).
Samples for molecular analysis were processed according to the manufacturer’s instructions
using the IRIDICA BAC BSI Assay (List Number 08N22-010, Ibis Biosciences-Abbott Molecu-
lar, Des Plaines, IL), leading to microbial identification from whole blood in 6–8 h. Up to 6
specimen may be tested in a single batch. As previously described [3, 30], this process consists
in an automated sample lysis using the IRIDICA Bead Beater (BB) instrument, an automated
nucleic acid extraction using the IRIDICA Sample Prep (SP) instrument, a PCR amplification
using the IRIDICA ThermoCycler (TC) instrument, an automated amplicon purification
using the IRIDICA Desalter (DS) instrument, an automated electrospray ionization time-of-
flight mass spectrometry using the IRIDICA Mass Spectrometer (MS) instrument and a
PCR/ESI-MS: Detection of sepsis-related pathogens
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bioinformatics data analysis with the IRIDICA Analysis Software (AS). Briefly, 5 mL whole
blood samples were chemically and mechanically lysed and an extraction control was added to
monitor the process. The extraction system uses prefilled disposable cartridges and the eluted
fluids were transferred into 16 wells of a custom PCR assay strip prefilled with PCR master
mix and 18 primer pairs for the efficient detection of BSI-related bacteria and Candida species,
as well as genes related to resistance to methicillin (mecA), vancomycin (vanA and vanB) and
carbapenems (KPC). Primer sequences, gene targets and PCR cycling configuration have been
described elsewhere in detail [24]. PCR products were then desalted by binding to magnetic
microparticles, washing and elution and lastly analysed through ESI-MS in automated system.
The base compositions of detected amplicon strands were calculated from the measured mas-
ses and compared with a reference database, which contained the complete amplicon signa-
tures for more than 780 Bacterial and Candida species [24–25]. The BAC BSI assay controls
were composed by an extraction control target added to each sample, an internal PCR calibra-
tor in each reaction well and a sterile buffer sample as the negative control in every run [3].
The PCR/ESI-MS results included a report of the organism names, level, and Q score. The
level was calculated with reference to the internal calibrator construct, as described previously
[30], and allowed a relative approximation of the concentration of any specific target. The Q
score ranged between 0 and 1 and it was a relative measure of the quality of the identification.
The Q score cut offs were designed to prevent specific identification when the information
obtained was not sufficient to confidently resolve an organism’s identity [24]. For this study, a
Q score of> 0.90 was considered a reportable result.
Data analysis
In order to determine the analytical performance of the IRIDICA System all the results
obtained with the PCR/ES MS assay were compared with those by standard microbiological
testing. A direct comparison between the microorganism isolated in the blood culture and the
microorganism detected by IRIDICA was made and matched positive or negative results for
each specimen were recorded. When discrepant results between the two methods were found,
a constructed “clinical infection criterion” was used to determine whether the discrepant
results were clinically significant or not. The clinical records of each individual patient that
had discrepant findings were reviewed in order to identify the diagnosed focus of infection, as
well as the results of cultures from other specimens available within a time frame of 7 days
after and 7 days before the IRIDICA test. McNemar test and Cohen κ were used to determine
agreement and concordance in the light of the evaluation of the clinical context.
Common contaminants, such as coagulase-negative staphylococci (CoNS), were considered
as potential contaminants for both methods and excluded from the overall analysis, unless
more than one set of blood culture was positive for the same organism, which is compatible
with a true infection [25, 31].
Results
The performance of the IRIDICA BAC BSI Assay was evaluated by comparison with the tradi-
tional culture-based methods routinely performed in our laboratory.
Of 300 patients enrolled in the study, 10 did not have matching PCR/ESI-MS or standard-
of-care microbiology results and were excluded from the final analysis.
In the absence of repeated positivity for known contaminants through multiple sets or a
clinical presentation favouring a different conclusion, a single positive result is likely to be the
consequence of a contamination event [25]. We therefore excluded from our analysis all the
samples positive for the most common contaminants, unless more than one set was positive
PCR/ESI-MS: Detection of sepsis-related pathogens
PLOS ONE | https://doi.org/10.1371/journal.pone.0197436 May 15, 2018 4 / 12
for the same organism, as described above in the methods section. The specimens excluded for
this reason were 29: 7 Propionibacterium acnes (24,14%); 7 Fungus not identified (24,14%); 3
Staphylococcus capitis (10,34%); 2 Staphylococcus haemolyticus (6,9%); 2 Staphylococcus hominis
(6,9%); 2 Pseudomonas fluorescens (6,9%); 1 Bacillus spp (3,45%); 1 Erwinia bilingiae (3,45%); 1
Staphylococcus auricularis (3,45%); 1 Streptococcus constellatus (3,45%); 1 Streptococcus salivar-
ius (3,45%); 1 Staphylococcus epidermidis (3,45%).
The organisms were detected from BSI with different frequencies that are shown in Fig 1.
The distributions of species identified by MALDI-TOF and those detected by PCR/ESI-MS
were overall similar.
As shown in Table 1, 222 of the included specimens were concordant, of which 151 yielded
negative results. The overall concordance was of 86% with a Cohen κ of 0.68 (95% CI 0,59–
0,77). 94 samples presented a positive result for blood culture, of which 71 were in agreement
with the molecular assay. The concordance of identification (calculated sensitivity) was there-
fore of 76% (95% CI, 67–85%), while the calculated assay specificity was of 90% (95% CI 85–
95%). Finally, the negative predictive value (NPV) was 87% (95% CI, 82–92%), while the posi-
tive predictive value (PPV) was of 82% (95% CI 74–90%).
59 specimens were matching at the species level, including 2 specimens showing dual detec-
tion. While primary identification was in agreement between the two techniques, a secondary
detection was found by PCR/ESI-MS in 6 samples, and by MALDI-TOF in a single instance;
in 5 cases, each method had at least a non-matching additional identification (Table 2).
In 18 samples, blood culture identified an organism that was not reported by PCR/ESI-MS
(Table 3). Conversely, PCR/ESI-MS reported a BSI relevant organism in 16 additional speci-
mens that were blood culture negative (Table 4). In 5 cases both methods detected at least one
microorganism, but there was no match between the identifications (Table 5).
Discussion
Of 300 patients enrolled in the study, we excluded 10 as they did not have corresponding PCR/
ESI-MS or standard-of-care microbiology results. As described above, we also excluded from
our analysis all samples suggestive of contamination, including fungi detected only by the IRI-
DICA instrument. All detections of fungi not further identified happened within a short time
frame and involved immunocompetent patients whose clinical presentation was not compati-
ble with fungiemia. These detections were therefore considered contaminations during the
samples processing. As a further confirmation, none of the patients involved was treated with
antimycotics and all of them were discharged with a positive outcome.
Of the included specimens, 222 were in agreement, of which 151 presented concordant neg-
ative results, 59 showed perfect concordance for the species identified, and 12 were concordant
for primary identification.
When PCR/ESI-MS and MALDI-TOF did not match the identification, further investiga-
tion was required regarding the reliability and significance of the data. This was achieved
reviewing the patients’ medical records, as well as the results of additional relevant exams from
other specimens available within a time window of 14 days. Q score and Level analysis did not
prove useful in the resolution of discrepancies: the Q scores of all samples were very high
(>96) within the range of reportability, with no significant differences between concordant
and discordant results. The Level score, conversely, showed extreme variability even within
concordant results, as this is not a quantitative test. It was therefore not possible to draw accu-
rate conclusions based on this parameter.
Of the 18 blood culture-positive, IRIDICA negative specimens (Table 2), clinical data pro-
vided strong support to the microbiology result in 15 cases; in 2 cases laboratory and clinical
PCR/ESI-MS: Detection of sepsis-related pathogens
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data were not compatible with true bacteremia, while in the remaining case the review of med-
ical records did not provide sufficient information to solve the discrepancy.
Of the 16 PCR/ESI-MS positive, blood culture-negative specimens (Table 3), the review of
individual medical record strongly suggested the high likelihood of bacteremia in 14 cases,
whereas in 1 sample, while plausible, clinical data were insufficient to reach a definite diagnosis
of sepsis. In the remaining case, IRIDICA detected N. meningitidis, a pathogen which presents
potentially severe clinical consequence. In addition to two negative sets of blood cultures, how-
ever, laboratory and clinical data were not compatible with meningococcemia, and the patient
was discharged without being treated for it. This makes an aspecific reaction during the PCR
more likely compared to true bacteremia.
In 5 patients, PCR/ESI-MS and blood culture showed a detection of un-matching organ-
isms (Table 4). In 4 of those cases, clinical data provided strong support to the microbiology
result; in the remaining sample, while a true bacteremia was strongly suggested, the medical
record did not provide sufficient information to determine the actual causative pathogen.
Only the former 4 samples were therefore included in the concordance and discordance calcu-
lations.Previous studies show a substantial heterogeneity regarding the performance of this
test [3, 25, 30, 32], with a review published in 2016 estimating a sensitivity of 81% and a speci-
ficity of 84% [33]. However, all of these studies support our conclusion that the IRIDICA BAC
BSI Assay has the ability to identify a broad range of bacteria directly from primary whole
blood samples, within eight hours. This might allow a timely administration of a suitable
treatment.
These results should nonetheless be confirmed in studies that can directly determine the
impact of this approach on clinical and economic outcomes, but also on resistance patterns.
The molecular assay presents some limitations. The provision of results to the clinician is
conditioned by several variables, such as the lack of random access to the instrument, which is
able to process up to 6 samples in a single batch. Additionally, the presence of an operator is
needed at several points during the analysis, amounting to a total hands-on time of approxi-
mately 1 h; also, a trained biologist is required to validate the end results. All these conditions
make scheduled runs a necessity, outside of which the provision of an end result might be
severely delayed, due to the variability in the time window between the collection of the sample
Fig 1. Distribution of the organisms included in the study. The organisms reported by culture (solid bar) and PCR/
ESI-MS (patterned bar) are sorted by decreasing order of PCR/ESI-MS reported organisms.
https://doi.org/10.1371/journal.pone.0197436.g001
Table 1. Assay performance.
Samples included, n 261
Matched negatives, n 151
Matched positives, n 59
Concordant primary identification with unmatched additional detections, n 12
IRIDICA-negative and blood culture-positive detections, n 18
IRIDICA-positive and blood culture-negative detections, n 16
Unmatching results, n 5
Concordance, % 86
Sensitivity, % 76
Specificity, % 90
PPV, % 82
NPV, % 87
https://doi.org/10.1371/journal.pone.0197436.t001
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and its processability. In addition, as the number of blood cultures drawn per day can exceed
100 in some hospitals, this platform is not suitable for all patients, requiring a strict selection
Table 2. Concordant primary pathogen identification with unmatched additional detections.
Primary organism(s) detected in concordant PCR/ESI-MS and culture results Additional detection result by:
PCR/ESI-MS Culture
Streptococcus spp. Odoribacter splanchnicus, Bilophila wadsworthia Sutterella wadsworthensis
Citrobacter freundii Klebsiella variicola Citrobacter brakii
Escherichia coli Pseudomonas aeruginosa None
Hafnia alvei Yersinia enterocolitica Serratia liquefaciens
Escherichia coli Clostridium perfringens Klebsiella oxytoca
Escherichia coli Klebsiella pneumoniae None
Escherichia coli Bacteroides fragilis None
Escherichia coli Klebsiella pneumoniae None
Pseudomonas aeruginosa Fusobacterium nucleatum Eubacterium lentum
Candida glabrata Lactobacillus johnsonii None
Enterobacter cloacae None Enterococcus faecalis
Klebsiella pneumoniae Fusobacterium nucleatum Enterococcus faecalis
https://doi.org/10.1371/journal.pone.0197436.t002
Table 3. IRIDICA-negative and blood culture-positive detections.
Blood culture-reported
organism with PCR/ESI-MS
negative result
No. of blood culture-
positive, PCR/ESI-MS-
negative samples
Medical records review
Staphylococcus epidermidis 4 Two cases: effective antibiotic treatment against
Staphylococcus epidermidis/One case: clinical data
insufficient/One case: true bacteremia unlikely
Pseudomonas aeruginosa 2 Urine culture positive for Pseudomonas aeruginosa/
Clinical diagnosis: sepsis Pseudomonas aeruginosa-
related
Streptococcus pneumoniae 2 Detection of Streptococcus pneumoniae urinary
antigen/Effective antibiotic treatment against
Streptococcus pneumoniae
Aeromonas salmonicida 1 Clinical presentation compatible with Aeromonas
spp. infection
Escherichia coli 1 Clinical diagnosis: sepsis Escherichia coli-related
from urinary tract infection
Enterococcus faecalis 1 One additional set of blood culture collected the
same day: Enterococcus faecalis
Streptococcus mitis 1 True bacteremia unlikely
Streptococcus intermedius 1 Clinical diagnosis: sepsis from respiratory tract
infection
Pseudomonas oryzihabitans 1 Clinical presentation compatible with Pseudomonas
spp. infection
Klebsiella pneumoniae 1 Urine culture positive for Klebsiella pneumoniae
Enterococcus faecium 1 Clinical diagnosis: sepsis Enteroccocus faecium-
related
Staphylococcus haemolyticus 1 Clinical diagnosis: sepsis Staphylococcus-related
Haemophilus parainfluenzae 1 Clinical diagnosis of sepsis
In 18 patients blood cultures identified a potential pathogen which was not detected by IRIDICA. The reliability of
these results was achieved reviewing the patients’ clinical data, as well as the results of additional relevant exams from
other specimens available.
https://doi.org/10.1371/journal.pone.0197436.t003
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on the clinicians’ part. Furthermore, PCR/ES-MS is unable to provide detailed antimicrobial
susceptibility information, unlike culture techniques, and is limited in terms of detecting resis-
tance-associated genes to mecA, vanA, vanB, and KPC. More importantly, the false negative
rate is too high to consider this assay suitable as a stand-alone test. For all these reasons, the
IRIDICA BAC BSI Assay could be considered a valuable tool if associated with the diagnostic
algorithm, but not a replacement for conventional methods.
Also, the PCR/ESI-MS and blood culture are sensitive both to BSI-related pathogens and
accidental contaminants introduced into the sample workflow. Sterile laboratory handling and
a rigorous technique during blood draws are therefore essential, along with the use of negative
controls in the molecular assay. The IRIDICA BC BSI Assay results should therefore be inter-
preted within the clinical context of the patient and additional laboratory results, similarly to
the current microbiology testing. In order to use this assay in routine, a better calibration of
Table 4. IRIDICA-positive and blood culture-negative detections.
PCR/ESI-MS-reported
organism with blood culture
negative result
No. of PCR/ESI-MS-
positive, blood culture-
negative samples
Medical records review
Escherichia coli 5 Urine culture positive for Escherichia coli/Effective
antibiotic treatment against Escherichia coli
Klebsiella pneumoniae 3 Urine culture positive for Klebsiella pneumoniae/
Clinical diagnosis of pneumoniae/Klebsiella
pneumoniae identified in aortic abscess
Pseudomonas aeruginosa 2 Clinical diagnosis: sepsis from urinary tract
infection
Legionella pneumophila 2 Detection of Legionella pneumophila urinary
antigen
Bartonella henselae 1 Positive serology for Bartonella henselae
Neisseria gonorrhoeae 1 Clinical diagnosis: pelviperitonitis Neisseria
gonorrhoeae-related
Neisseria meningitidis 1 Clinical data insufficient
Streptococcus agalactiae 1 Clinical presentation compatible with Streptococcus
agalactiae infection
In 16 patients a potential pathogen was detected by the molecular method but not by MALDI-TOF. The review of
clinical data and additional relevant exams from other specimens was used for the resolution of discrepancies.
https://doi.org/10.1371/journal.pone.0197436.t004
Table 5. Unmatching results between the two methods.
Sample
ID
Organism(s) identified by PCR/ESI-MS Organism(s) identified by blood
culture test
Relevant additional exams
A. Klebsiella oxytoca Proteus mirabilis Urine colture result on sample collected the same day: Proteus
mirabilis
B. Bacillus circulans, Aerococcus urinae,
Peptoniphilus asaccharolyticus
Proteus mirabilis, Enterococcus faecalis Four additional sets of blood culture collected the same day:
Proteus mirabilis, Enterococcus faecalis
C. Prevotella oris Escherichia coli, Bacteroides fragilis,
Eubacterium lentum
One additional set of blood colture collected the same day:
Escherichia Coli
D. Haemophilus influenzae Staphylococcus aureus One set of blood colture collected the day before: Staphylococcus
aureus
E. Escherichia coli Staphylococcus aureus None
In 5 cases IRIDICA and blood culture were positive for different targets. The results of additional relevant exams from other specimens were reviewed in order to
identify the diagnosed focus of infection.
https://doi.org/10.1371/journal.pone.0197436.t005
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the reportability cut-off is needed, considering the high false negative rate. The possibility of
random access to the instrument and the capability to process more than 6 samples simulta-
neously would also be useful improvements.
Additional studies would be required to evaluate the impact on the turnaround time and
the consequent clinical management for this laboratory technology.
Acknowledgments
We thank the heads and all the personnel of the units enrolled in this study: Emergency Room
and Emergency Medicine Units—Bufalini Hospital (Cesena, Italy), Santa Maria delle Croci
Hospital (Ravenna, Italy), Infermi Hospital (Rimini, Italy); Infectious Diseases Unit—Mor-
gagni-Pierantoni Hospital (Forlı`, Italy), Emergency Medicine Unit—Umberto I Hospital
(Lugo, Italy).
Author Contributions
Conceptualization: Martina Tassinari, Silvia Zannoli, Vittorio Sambri.
Data curation: Martina Tassinari, Silvia Zannoli.
Formal analysis: Martina Tassinari, Silvia Zannoli.
Funding acquisition: Vittorio Sambri.
Investigation: Martina Tassinari, Silvia Zannoli.
Project administration: Patrizia Farabegoli, Maria Federica Pedna, Anna Pierro, Vittorio
Sambri.
Resources: Patrizia Farabegoli, Maria Federica Pedna, Anna Pierro, Antonio Mastroianni,
Riccardo Fontan, Luciano Luongo, Giuseppe Sarnataro, Elisa Menegatti, Assunta Caruso,
Vittorio Sambri.
Supervision: Patrizia Farabegoli, Maria Federica Pedna, Anna Pierro.
Validation: Martina Tassinari, Silvia Zannoli, Patrizia Farabegoli, Maria Federica Pedna.
Visualization: Martina Tassinari, Silvia Zannoli, Anna Pierro.
Writing – original draft: Martina Tassinari, Silvia Zannoli.
Writing – review & editing: Maria Federica Pedna, Vittorio Sambri.
References
1. Riedel S, Carroll KC. Laboratory detection of sepsis: biomarkers and molecular approaches. Clin Lab
Med. 2013; 33(3): 413–443. https://doi.org/10.1016/j.cll.2013.03.006 PMID: 23931833
2. Lodes U, Bohmeier B, Lippert H, Ko¨nig B, Meyer F. PCR-based rapid sepsis diagnosis effectively
guides clinical treatment in patients with new onset of SIRS. Langenbecks Arch Surg. 2012; 397(3):
447–455. https://doi.org/10.1007/s00423-011-0870-z PMID: 22109826
3. Metzgar D, Frinder MW, Rothman RE, Peterson S, Carroll KC, Zhang SX, et al. The IRIDICA BAC BSI
Assay: Rapid, Sensitive and Culture-Independent Identification of Bacteria and Candida in Blood. PLoS
One. 2016; 11(7): e0158186 https://doi.org/10.1371/journal.pone.0158186 PMID: 27384540
4. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and out-
come of severe sepsis in French intensive care units. Intensive Care Med. 2004; 30(4): 580–588.
https://doi.org/10.1007/s00134-003-2121-4 PMID: 14997295
5. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with
ventilator-associated pneumonia and blood stream infection: A meta-analysis. J. Crit. Care. 2008; 23:
91–100. https://doi.org/10.1016/j.jcrc.2007.08.007 PMID: 18359426
PCR/ESI-MS: Detection of sepsis-related pathogens
PLOS ONE | https://doi.org/10.1371/journal.pone.0197436 May 15, 2018 10 / 12
6. Lyle N, Boyd J. The potential for PCR based testing to improve diagnosis and treatment of sepsis. Curr
Infect Dis Rep. 2013; 15(5): 372–379. https://doi.org/10.1007/s11908-013-0350-4 PMID: 23929539
7. Westh H, Lisby G, Breysse F, Bo¨ddinghaus B, Chomarat M, Gant V, et al. Multiplex real-time PCR and
blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Micro-
biol Infect. 2009; 15(6): 544–551.
8. Paolucci M, Landini MP, Sambri V. How can the microbiologist help in diagnosing neonatal sepsis? Int J
Pediatr. 2012; 2012:120139. https://doi.org/10.1155/2012/120139 PMID: 22319539
9. Mancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, et al. Cost-effectiveness of blood cul-
ture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational
propensity score-matched study. Expert Rev Mol Diagn. 2014; 14(5): 623–632. https://doi.org/10.1586/
14737159.2014.916212 PMID: 24844138
10. Lehmann LE, Hunfeld KP, Steinbrucker M, Brade V, Book M, Seifert H, et al. Improved detection of
blood stream pathogens by real-time PCR in severe sepsis. Intensive Care Med. 2010; 36(1): 49–56.
https://doi.org/10.1007/s00134-009-1608-z PMID: 19756512
11. Paolucci M, Landini MP, Sambri V. Conventional and molecular techniques for the early diagnosis of
bacteraemia. Int J Antimicrob Agents. 2010; 36 Suppl 2: S6–16.
12. Gaibani P, Rossini G, Ambretti S, Gelsomino F, Pierro AM, Varani S, et al. Blood culture systems: rapid
detection—how and why? Int J Antimicrob Agents. 2009; 34 Suppl 4: S13–5.
13. Congestrı` F, Pedna MF, Fantini M, Samuelli M, Schiavone P, Torri A, et al. Comparison of ’time to
detection’ values between BacT/ALERT VIRTUO and BacT/ALERT 3D instruments for clinical blood
culture samples. Int J Infect Dis. 2017; 62: 1–5. https://doi.org/10.1016/j.ijid.2017.06.012 PMID:
28625838
14. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treat-
ment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118(1): 146–155.
PMID: 10893372
15. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it
right up front. Clin Infect Dis. 2008. 47 Suppl 1:S3–13.
16. Rhodes J, Hyder JA, Peruski LF, Fisher C, Jorakate P, Kaewpan A, et al. Antibiotic use in Thailand:
quantifying impact on blood culture yield and estimates of pneumococcal bacteremia incidence. Am J
Trop Med Hyg. 2010; 83(2): 301–306. https://doi.org/10.4269/ajtmh.2010.09-0584 PMID: 20682872
17. Paolucci M, Capretti MG, Dal Monte P, Corvaglia L, Landini MP, Varani S, et al. Laboratory diagnosis of
late-onset sepsis in newborns by multiplex real-time PCR. J Med Microbiol. 2009; 58(4): 533–534.
18. Varani S, Stanzani M, Paolucci M, Melchionda F, Castellani G, Nardi L, et al. Diagnosis of bloodstream
infections in immunocompromised patients by real-time PCR. J Infect. 2009; 58(5): 346–351. https://
doi.org/10.1016/j.jinf.2009.03.001 PMID: 19362374
19. Josefson P, Strålin K, Ohlin A, Ennefors T, Dragsten B, Andersson L, et al. Evaluation of a commercial
multiplex PCR test (SeptiFast) in the etiological diagnosis of community-onset bloodstream infections.
Eur J Clin Microbiol Infect Dis. 2011; 30(9): 1127–1134. https://doi.org/10.1007/s10096-011-1201-6
PMID: 21373774
20. Schreiber J, Nierhaus A, Braune SA, de Heer G, Kluge S. Comparison of three different commercial
PCR assays for the detection of pathogens in critically ill sepsis patients. Med Klin Intensivmed
Notfmed. 2013; 108(4): 311–318. https://doi.org/10.1007/s00063-013-0227-1 PMID: 23516029
21. Ecker DJ, Sampath R, Li H, Massire C, Matthews HE, Toleno D et al. New technology for rapid molecu-
lar diagnosis of bloodstream infections. Expert Rev Mol Diagn. 2010; 10(4):399–415. https://doi.org/10.
1586/erm.10.24 PMID: 20465496
22. Paolucci M, Stanzani M, Melchionda F, Tolomelli G, Castellani G, Landini MP, et al. Routine use of a
real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic
patients. Diagn Microbiol Infect Dis. 2013; 75(2): 130–134. https://doi.org/10.1016/j.diagmicrobio.2012.
10.012 PMID: 23177222
23. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria.
Int J Antimicrob Agents. 2007; 30 Suppl 1: S7–15.
24. Bacconi A, Richmond GS, Baroldi MA, Laffler TG, Blyn LB, Carolan HE, et al. Improved sensitivity for
molecular detection and identification of bacteria and Candida in blood. J Clin Microbiol. 2014; 52(9):
3164–3174. https://doi.org/10.1128/JCM.00801-14 PMID: 24951806
25. Laffler TG, Cummins LL, McClain CM, Quinn CD, Toro MA, Carolan HE, et al. Enhanced diagnostic
yields of bacteremia and candidemia in blood specimens by PCR-electrospray ionization mass spec-
trometry. J Clin Microbiol. 2013; 51(11): 3535–3541. https://doi.org/10.1128/JCM.00876-13 PMID:
23966503
PCR/ESI-MS: Detection of sepsis-related pathogens
PLOS ONE | https://doi.org/10.1371/journal.pone.0197436 May 15, 2018 11 / 12
26. Metzgar D, Sampath R, Blyn LB, Massire C, Ecker DJ. Microbial Identification by PCR/Electrospray Ion-
ization-Mass Spectrometry. Advanced Techniques in Diagnostic Microbiology. 2012; Pp 441–465.
27. Ecker DJ, Massire C, Blyn LB, Hofstadler SA, Hannis JC, Eshoo MW, et al. Molecular genotyping of
microbes by multilocus PCR and mass spectrometry: a new tool for hospital infection control and public
health surveillance. Methods Mol Biol. 2009; 551: 71–87. https://doi.org/10.1007/978-1-60327-999-4_7
PMID: 19521868
28. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third Inter-
national Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801–10.
https://doi.org/10.1001/jama.2016.0287 PMID: 26903338
29. Weinstein MP, Doern GV. A critical appraisal of the role of the clinical microbiology laboratory in the
diagnosis of bloodstream infections. J Clin Microbiol. 2011; 49 (9 Supplement): S26–S29.
30. Jordana-Lluch E, Rivaya B, MarcòC, Gimènez M, Quesada MD, Escobedo A, et al. Molecular diagno-
sis of bloodstream infections in onco-haematology patients with PCR/ESI-MS technology. J Infect.
2017; 74(2): 187–194. https://doi.org/10.1016/j.jinf.2016.11.011 PMID: 27889413
31. Weinstein MP. Blood culture contamination: persisting problems and partial progress. J Clin Microbiol.
2003; 41(6): 2275–2278. https://doi.org/10.1128/JCM.41.6.2275-2278.2003 PMID: 12791835
32. Vincent JL, Brealey D, Libert N, Abidi NE, O’Dwyer M, Zacharowski K, et al. Rapid Diagnosis of Infec-
tion in the Critically Ill, a Multicenter Study of Molecular Detection in Bloostream Infections, Pneumonia,
and Sterile Site Infections. Crit Care Med. 2015; 43(11): 2283–2291. https://doi.org/10.1097/CCM.
0000000000001249 PMID: 26327198
33. Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, et al. Sepsis: the LightCycler
SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying blood-
stream bacteria and fungi—a systematic review and economic evaluation. Health Technol Assess.
2016; 20(46): 1–246. https://doi.org/10.3310/hta20460 PMID: 27355222
PCR/ESI-MS: Detection of sepsis-related pathogens
PLOS ONE | https://doi.org/10.1371/journal.pone.0197436 May 15, 2018 12 / 12
